USD
+$0.00
(+0.00%
)At Close (As of Oct 16, 2025)
$18.22M
Market Cap
-
P/E Ratio
-26.32
EPS
$19.20
52 Week High
$2.68
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$2.9M |
Total Revenue | $0 |
Cost Of Revenue | $2.9M |
Costof Goods And Services Sold | $2.9M |
Operating Income | -$60M |
Selling General And Administrative | $16M |
Research And Development | $41M |
Operating Expenses | $60M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | - |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $2.9M |
Income Before Tax | -$56M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$56M |
Comprehensive Income Net Of Tax | - |
Ebit | -$57M |
Ebitda | -$54M |
Net Income | -$56M |
Field | Value (USD) |
---|---|
Total Assets | $81M |
Total Current Assets | $72M |
Cash And Cash Equivalents At Carrying Value | $28M |
Cash And Short Term Investments | $28M |
Inventory | - |
Current Net Receivables | $300K |
Total Non Current Assets | $9.1M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $41M |
Other Current Assets | $2.9M |
Other Non Current Assets | - |
Total Liabilities | $15M |
Total Current Liabilities | $9.6M |
Current Accounts Payable | $5.4M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $796K |
Total Non Current Liabilities | $5.8M |
Capital Lease Obligations | $5.9M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $5.9M |
Other Current Liabilities | $3.4M |
Other Non Current Liabilities | $661K |
Total Shareholder Equity | $65M |
Treasury Stock | - |
Retained Earnings | -$380M |
Common Stock | $28K |
Common Stock Shares Outstanding | $2.3M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$41M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $2.9M |
Capital Expenditures | $474K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | $55M |
Cashflow From Financing | $144K |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$56M |
Field | Value (USD) |
---|---|
Gross Profit | -$2.9M |
Total Revenue | $0 |
Cost Of Revenue | $2.9M |
Costof Goods And Services Sold | $2.9M |
Operating Income | -$60M |
Selling General And Administrative | $16M |
Research And Development | $41M |
Operating Expenses | $60M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | - |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $2.9M |
Income Before Tax | -$56M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$56M |
Comprehensive Income Net Of Tax | - |
Ebit | -$57M |
Ebitda | -$54M |
Net Income | -$56M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
NextCure, Inc. (NXTC) is a clinical-stage biopharmaceutical firm located in Beltsville, Maryland, dedicated to pioneering immunomedicines for cancer and various immune-related disorders. Utilizing its advanced NEX-T technology platform, the company aims to restore and optimize immune function, thereby developing innovative treatment options for patients with significant therapeutic gaps. With a robust pipeline and a commitment to addressing pressing healthcare challenges, NextCure is strategically positioned to play a vital role in the burgeoning immunotherapy landscape.